罗格列酮对多囊卵巢综合症患者胰岛素抵抗状态及血脂、性激素和排卵的影响被引量：6

Roslglitazone Effect on Polycystic Ovary Syndrome: Relationship to Blood-adipose, Sex Hormone and Ovulation

下载PDF

导出

摘要目的探讨多囊卵巢综合症(PCOS)患者胰岛素抵抗与脂代谢和排卵的关系。方法测定25例PCOS患者和15例非内分泌因素不孕症妇女的性激素、血脂、胰岛素(Ins)水平,其中PCOS患者进行口服糖耐量试验(OGTT)。OGTT提示胰岛素抵抗(IR)者给予罗格列酮(4mg/d)治疗,并促排卵药物治疗,3月后复测上述血清指标。结果PCOS患者经治疗后血清Ins、胆固醇、甘油三酯、高密度脂蛋白水平显著降低,排卵率增加,IR状态改善。结论血脂异常是PCOS患者临床表现之一,IR和高胰岛素血症是PCOS患者血脂异常的重要原因。罗格列酮阻断IR对PCOS发展的促进作用,改善PCOS的血脂紊乱,增加排卵的发生。 Objective To investigate the effects of roslglitazone on polycystic ovary syndrome （PCOS） and its relationship to insulin-resistance （IR） , blood-adipose metabolism and ovulation. Methods Serum levels of sex hormone, blood-adipose, fasting insulin were determined in both PCOS group and controls （fifteen infertility patients） and glucose tolerance test in PCOS groups. Roslglitazone and acceleration ovulation therapy were gived （4mg/d） in PCOS with IR. Results Mean （±SEM） concentrations of insuin, total cholesterol, triglyceride and high density lipoprotein were decreased and ovulation rate were rised significant in PCOS treated with roslglitazone. Conclusion Disorder metabolism of blood-adipose is a clinical situation of PCOS and it principal caused by IR and hyperinsulinemia. The disorder can be treated by roslglitazone.

作者余进进陈小平陆英华史怀吴海燕

机构地区苏州大学附属第四医院

出处《中国血液流变学杂志》 CAS 2005年第2期286-288,共3页 Chinese Journal of Hemorheology

关键词多囊卵巢综合症胰岛素抵抗罗格列酮排卵 polycystic ovary syndrome insulin-resistance roslglitazone ovulation

分类号 R711.75 [医药卫生—妇产科学]

引文网络
相关文献

参考文献11

1张翠莲,高航云,赵志刚,贾萍.罗格列酮用于多囊卵巢综合征促排卵治疗的效果观察[J].中华妇产科杂志,2004,39(3):173-175. 被引量：11
2Legro RS,Finegood D,Dunaif A.A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome[J].J Clin Endocrinol Metab,1998,83:2694.
3Azziz R,Rittmaster RS,Fox LM,et al. Role of the ovary in the adrenal androgen:excess of hyperandrogeric women[J]. Fertil steril ,1998,69(5):851～859.
4Wild RA ,Alaupovicp,Parker IJ.Lipid and apolipoprotein abnormalities in hirsute women:the association with insulin resistance[J].Am J Obstet Gynecol,1992,166(4):1191～1196.
5Dunaif A ,Scottt D,et al.The insulin-sensitizing agent troglitazone improves metabolic and reprodultive abnormalities in the polycystic ovary syndrome[J].J clin Endocrinol,1996,81:3299～3306.
6Ehrmann DA ,Schneider DJ,Sobel BE ,et al .Troglitazone improves defects in insulin action ,insulin secretion,steroidogenesis,and fibrinolysis in women with polycystic ovary syndrome[J].J clin Endocrinol Metab,1997,82:2108～2116.
7Hasegawa I ,Murakawa H ,Suzuki M,et al.Effect of troglitazone on endocrine and ovulatory performance in woman with insulin resistance-related polycystic ovary syndrome[J].Fertil steril,1999,71:323～327.
8Nestler JE ,Jakubowicz DJ .Decreases in ovarian cytochrome p450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome[J].N Engl J med,1996,335:617～623.
9Unger JW ,Livingston JN,Moss AM.Insulin receptors in the central nervous system:localization,signaling mechanisms and functional aspects[J].Prog Neurobiol,1999,36:343～362.
10Azziz R,Ehrmann D,Lagro RS,et al.PCOS Mroglitazone study Group .Troglitazone improvea ovulation and birautian in the polysystic ovary syndrome: a multicenter, double blind placebo-controlled trial[J].J clin Endocrinol Metab,2001,86:1626～1632,5090～5091.